ALTA3263 for advanced KRAS-mutated solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a KRAS mutation that was found by a standard genetic test.
- Your cancer must be advanced (spread or can't be removed) and you've tried other treatments or can't take them.
- You must be able to take care of yourself (up and about more than 50% of the time).
- Your organs (kidneys, liver, etc.) must work well enough.
- You cannot have taken a KRAS-targeting drug before (like sotorasib or adagrasib), and you must be able to swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called LT-010391 designed to target a specific genetic mutation (KRAS G12D) found in some solid tumors. It's for patients whose cancer has progressed despite standard treatments or who cannot tolerate them.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This study tests a new drug called KQB368 for advanced solid cancers that have a specific genetic change (KRAS G12C or G12S mutation). The drug is designed to target this mutation and may help slow or shrink tumors in patients who don't have other curative treatment options.
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
This trial tests a new drug called TLN-372 for people with advanced solid tumors that have a KRAS mutation. It aims to see if the drug is safe and effective for these cancers.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.